Willem W. Overwijk

17.2k total citations · 4 hit papers
112 papers, 9.6k citations indexed

About

Willem W. Overwijk is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Willem W. Overwijk has authored 112 papers receiving a total of 9.6k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Immunology, 64 papers in Oncology and 26 papers in Molecular Biology. Recurrent topics in Willem W. Overwijk's work include Immunotherapy and Immune Responses (81 papers), CAR-T cell therapy research (40 papers) and Cancer Immunotherapy and Biomarkers (36 papers). Willem W. Overwijk is often cited by papers focused on Immunotherapy and Immune Responses (81 papers), CAR-T cell therapy research (40 papers) and Cancer Immunotherapy and Biomarkers (36 papers). Willem W. Overwijk collaborates with scholars based in United States, Australia and Netherlands. Willem W. Overwijk's co-authors include Nicholas P. Restifo, Patrick Hwu, Deborah R. Surman, Steven A. Rosenberg, Gregory Lizée, Chengwen Liu, Yared Hailemichael, Yanyan Lou, Bernard Moss and Miles W. Carroll and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Willem W. Overwijk

110 papers receiving 9.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells

2003 751 citations Willem W. Overwijk, Marc R. Theoret et al. profile →
T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity

2009 618 citations Patrick Hwu, Nicholas P. Restifo et al. profile →
CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells

2005 585 citations Paul A. Antony, Ciriaco A. Piccirillo et al. The Journal of Immunology profile →
Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy

2017 308 citations Tiffany R. Hodges, Martina Ott et al. Neuro-Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Willem W. Overwijk United States	49	7.1k	4.9k	2.7k	931	558	112	9.6k
Bernard A. Fox United States	48	4.4k 0.6×	4.4k 0.9×	2.2k 0.8×	954 1.0×	501 0.9×	200	7.6k
Chrystal M. Paulos United States	39	5.5k 0.8×	5.4k 1.1×	2.3k 0.9×	1.1k 1.1×	436 0.8×	132	9.2k
James J. Mulé United States	60	9.1k 1.3×	6.1k 1.2×	3.6k 1.3×	1.5k 1.7×	813 1.5×	167	12.8k
Christoph Huber Germany	45	5.0k 0.7×	3.5k 0.7×	3.3k 1.2×	904 1.0×	504 0.9×	155	8.6k
Christopher A. Klebanoff United States	41	7.9k 1.1×	7.9k 1.6×	3.0k 1.1×	1.7k 1.9×	685 1.2×	77	11.7k
Sandra Hervás‐Stubbs Spain	39	3.7k 0.5×	2.8k 0.6×	2.1k 0.8×	591 0.6×	565 1.0×	111	6.7k
Radek Špíšek Czechia	45	4.8k 0.7×	3.3k 0.7×	1.9k 0.7×	431 0.5×	464 0.8×	134	7.6k
Karine Breckpot Belgium	54	4.5k 0.6×	3.2k 0.7×	3.4k 1.3×	1.1k 1.2×	348 0.6×	170	7.6k
Chiara Castelli Italy	46	5.8k 0.8×	4.8k 1.0×	4.4k 1.6×	488 0.5×	1.3k 2.3×	127	10.2k
Hideaki Tahara Japan	51	5.1k 0.7×	3.5k 0.7×	3.6k 1.3×	1.9k 2.0×	489 0.9×	172	9.0k

Countries citing papers authored by Willem W. Overwijk

Since Specialization

Citations

This map shows the geographic impact of Willem W. Overwijk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Willem W. Overwijk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Willem W. Overwijk more than expected).

Fields of papers citing papers by Willem W. Overwijk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Willem W. Overwijk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Willem W. Overwijk. The network helps show where Willem W. Overwijk may publish in the future.

Co-authorship network of co-authors of Willem W. Overwijk

This figure shows the co-authorship network connecting the top 25 collaborators of Willem W. Overwijk. A scholar is included among the top collaborators of Willem W. Overwijk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Willem W. Overwijk. Willem W. Overwijk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hai, Hoang, Yaya Chu, Yanling Liao, et al.. (2024). Combinatorial immunotherapy of anti-MCAM CAR-modified expanded natural killer cells and NKTR-255 against neuroblastoma. PubMed. 32(4). 200894–200894.

Hirayama, Alexandre V., Cassie Chou, Takahiro Miyazaki, et al.. (2022). A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy. Blood Advances. 7(11). 2479–2493. 14 indexed citations

Encinas, Jessica, Yao Yao, Yan Xu, et al.. (2022). Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15. Blood Advances. 7(1). 9–19. 17 indexed citations

Pieper, Alexander, Alexander L. Rakhmilevich, Ravi B. Patel, et al.. (2021). Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice. Journal for ImmunoTherapy of Cancer. 9(6). e002715–e002715. 29 indexed citations

Overwijk, Willem W., Mary Tagliaferri, & Jonathan Zalevsky. (2020). Engineering IL-2 to Give New Life to T Cell Immunotherapy. Annual Review of Medicine. 72(1). 281–311. 94 indexed citations

Alatrash, Gheath, Na Qiao, Pariya Sukhumalchandra, et al.. (2019). Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes. Clinical Cancer Research. 25(8). 2610–2620. 21 indexed citations

Zhao, Jun, Huamin Wang, Diana S‐L Chow, et al.. (2018). Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy. Biomaterials. 159. 215–228. 110 indexed citations

Khong, Hiep, Meenu Sharma, Zhimin Dai, et al.. (2018). Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8+ T Cell Response. The Journal of Immunology. 200(10). 3464–3474. 13 indexed citations

Ritthipichai, Krit, Cara Haymaker, Xiaohui Yi, et al.. (2017). Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter. Clinical Cancer Research. 23(20). 6151–6164. 54 indexed citations

10.

Hodges, Tiffany R., Martina Ott, Joanne Xiu, et al.. (2017). Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro-Oncology. 19(8). 1047–1057. 308 indexed citations breakdown →

11.

Sim, Geok Choo, Chengwen Liu, Ena Wang, et al.. (2016). IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation. Cancer Immunology Research. 4(11). 983–994. 36 indexed citations

12.

Hailemichael, Yared & Willem W. Overwijk. (2014). Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination. The International Journal of Biochemistry & Cell Biology. 53. 46–50. 14 indexed citations

13.

Peng, Weiyi, Chengwen Liu, Chunyu Xu, et al.. (2012). PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines. Cancer Research. 72(20). 5209–5218. 340 indexed citations

14.

Sikora, Andrew G., Alexander Gelbard, Michael A. Davies, et al.. (2010). Targeted Inhibition of Inducible Nitric Oxide Synthase Inhibits Growth of Human Melanoma In vivo and Synergizes with Chemotherapy. Clinical Cancer Research. 16(6). 1834–1844. 107 indexed citations

15.

Peng, Weiyi, Yang Ye, Brian Rabinovich, et al.. (2010). Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses. Clinical Cancer Research. 16(22). 5458–5468. 173 indexed citations

16.

Kong, Ling-Yuan, Alexander Gelbard, Jun Wei, et al.. (2010). Inhibition of p-STAT3 Enhances IFN-α Efficacy against Metastatic Melanoma in a Murine Model. Clinical Cancer Research. 16(9). 2550–2561. 36 indexed citations

17.

Overwijk, Willem W., Karin E. de Visser, Felicia H. Tirion, et al.. (2006). Immunological and Antitumor Effects of IL-23 as a Cancer Vaccine Adjuvant. The Journal of Immunology. 176(9). 5213–5222. 67 indexed citations

18.

Antony, Paul A., Ciriaco A. Piccirillo, Akgül Akpınarlı, et al.. (2005). CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells. The Journal of Immunology. 174(5). 2591–2601. 585 indexed citations breakdown →

19.

O’Toole, Margot, et al.. (2000). Dose-Dependent and Schedule-Dependent Effects of Interleukin-12 on Antigen-Specific CD8 Responses. Journal of Interferon & Cytokine Research. 20(6). 589–596. 11 indexed citations

20.

Surman, Deborah R., Mark E. Dudley, Willem W. Overwijk, & Nicholas P. Restifo. (2000). Cutting Edge: CD4+ T Cell Control of CD8+ T Cell Reactivity to a Model Tumor Antigen. The Journal of Immunology. 164(2). 562–565. 138 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact